Kadmus has developed products for a variety of conditions through the inhibition of endocannabinoid degradation (FAAH inhibitors), activation of endocannabinoid related pathways (OEA), and activation of peripheral cannabinoid receptors.
Company (Alive / Active)
California, United States
|Investor||Investor Type||Location||Participating Rounds|
|Title||Application Date||Patent Date||Status
(Patent / Application)